Ziltivekimab Falls Short for Cutting Cardiovascular Events in ASCVD, CKD
(MedPage Today) -- Despite lowering inflammatory markers, treatment with the monoclonal antibody ziltivekimab did not reduce cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.